Haloperidol Tablets Rx
Generic Name and Formulations:
Haloperidol 0.5mg, 1mg, 2mg, 5mg, 10mg, 20mg; scored tabs.
Various generic manufacturers
Indications for Haloperidol Tablets:
Psychosis. Tourette's disorder. For severe behavior disorders or as a short-term treatment for hyperactivity in children who are refractory to psychotherapy or other medications.
Individualize. Initially: Moderate symptoms: 0.5mg–2mg 2–3 times daily. Severe, chronic, or resistant symptoms: 3mg–5mg 2–3 times daily. Debilitated: 0.5mg–2mg 2–3 times daily. Max: 100mg/day.
<3yrs: not recommended. Total dose may be divided, to be given 2–3 times daily. ≥3yrs: initially 0.5mg daily, may increase at increments of 0.5mg at 5–7 day intervals. Psychosis: 0.05mg/kg/day–0.15mg/kg/day. Nonpsychotic behavior and Tourette's: 0.05mg/kg/day–0.075mg/kg/day. Max 6mg/day.
Initially 0.5mg–2mg 2–3 times daily.
Severe CNS depression. Coma. Parkinsonism.
Increased mortality in elderly patients with dementia-related psychosis.
Elderly with dementia-related psychosis (not approved use): increased risk of death. Risk of QT prolongation: electrolyte disturbances (eg, hypokalemia, hypomagnesemia), underlying cardiac abnormalities, hypothyroidism, familial long QT-syndrome, concomitant drugs known to prolong the QT interval. Seizures. Thyrotoxicosis. Pre-existing low WBCs or history of leukopenia/neutropenia; monitor CBCs during 1st few months of treatment; discontinue if WBCs decline. Severe cardiovascular disorders. Mania. Avoid abrupt cessation. Debilitated. Neonates: risk of extrapyramidal and/or withdrawal symptoms post delivery (due to exposure during 3rd-trimester pregnancy). Pregnancy. Nursing mothers: not recommended.
CNS depression potentiated with alcohol, other CNS depressants. Possible neurotoxicity with lithium: monitor, discontinue if occurs. Caution with drugs that prolong the QT interval (eg, ketoconazole, paroxetine). May be potentiated by CYP3A4 inhibitors/substrates or CYP2D6 enzymes (eg, itraconazole, nefazodone, buspirone, venlafaxine, alprazolam, fluvoxamine, quinidine, fluoxetine, sertraline, chlorpromazine, promethazine. May be antagonized by CYP3A4 inducers (eg, rifampin, carbamazepine); monitor and adjust doses. May increase intraocular pressure with anticholinergics. Monitor anticoagulants.
Tardive dyskinesia, extrapyramidal symptoms, CNS effects, GI upset, cardiovascular effects, bronchopneumonia, neuroleptic malignant syndrome.
Formerly known under the brand name Haldol.
Sign Up for Free e-newsletters
Psychiatry Advisor Articles
- Nomophobia: The Modern-Day Pathology
- Emerging Theories in the Pathophysiology of MDD: Could the Opioid System Be Involved?
- Transdermal Nicotine Boosts Mood and Cognitive Function in Late-Life Depression
- Combination Cognitive Behavioral Therapy With Fluoxetine Effective for Adolescent Depression
- Ketamine Infusions Reduce Suicidal Ideation in Depression: Characterizing Different Responses
- Text Message Reminders Improve Medication Adherence in Bipolar I Disorder
- Improving Medication Adherence in ADHD Lowers Risk for Oppositional Defiant Disorder, Conduct Disorder in Adulthood
- High Suicidality Among Children With ADHD Mediated by Family Functioning, Psychiatry Comorbidities
- Pilot Study Investigates Lithium vs Quetiapine for Bipolar Spectrum Disorder
- How Personalized Hospital Ratings May Drive Patient-Specific Care in the Digital Age